{"release":"wpf-claim-checks","version":"1.6.0","checkedOn":"2026-11-14","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"single-peptide-evidence-combined-use","claimWording":"Each of these peptides has evidence behind it, so taking them together must be safe and work.","wordingKind":"representative","quoted":null,"title":"Evidence on single peptides versus taking them together","peptides":["semaglutide","cagrilintide"],"aliases":["CagriSema","REDEFINE 1","REDEFINE 5","combination","stack","taking together"],"topics":["safety","effectiveness","interpretation"],"verdict":"insufficient_evidence","plainAnswer":"Evidence on each peptide alone is not enough to say what happens when they are used together. The one combination checked here, cagrilintide with semaglutide (CagriSema), was tested in a randomized trial against each component and placebo, and the paper's abstract says its efficacy was unknown beforehand. The results apply to that combination in that trial's population and say nothing about other combinations.","scope":{"population":"Adults without diabetes with overweight or obesity (REDEFINE 1: 3,417 randomized; 68 weeks), plus one east Asian trial (REDEFINE 5: 331 randomized)","design":"REDEFINE 1: randomized 21:3:3:7 to the combination, semaglutide alone, cagrilintide alone or placebo, plus lifestyle intervention, with effects estimated by the treatment-policy estimand","boundary":"One combination in the trial populations, under trial conditions. It says nothing about any other combination, about use outside a trial, or about dosing. No recommendation is made."},"strongest":[{"label":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1; N Engl J Med, 2025; PMID 40544433; DOI 10.1056/NEJMoa2502081)","url":"https://pubmed.ncbi.nlm.nih.gov/40544433/","kind":"Peer-reviewed paper","population":"3,417 adults without diabetes with BMI of 30 or more, or 27 or more with an obesity-related complication","design":"Phase 3a, 68-week, double-blind, placebo-controlled and active-controlled randomized trial; funded by Novo Nordisk","locator":"Abstract. Background: the efficacy of the combination \"is unknown\". Methods: randomization 21:3:3:7 to the combination, semaglutide alone, cagrilintide alone or placebo; treatment-policy estimand. Results: 2,108, 302, 302 and 705 randomized; week-68 mean change in body weight -20.4% with the combination and -3.0% with placebo (estimated difference -17.3 percentage points; 95% CI -18.1 to -16.6; P<0.001); gastrointestinal adverse events 79.6% with the combination and 39.9% with placebo, described as mainly transient and mild-to-moderate. The abstract does not state the safety analysis population."},{"label":"Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: a secondary, post hoc analysis of REDEFINE 1 (Diabetes Obes Metab, 2026; PMID 42503495; PMC13538786)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13538786/","kind":"Peer-reviewed paper","population":"REDEFINE 1 participants with data at week 68: 1,444 (combination), 220 (semaglutide alone), 223 (cagrilintide alone), 451 (placebo)","design":"Secondary, post hoc analysis of observed on-treatment data; authors include employees of the trial sponsor","locator":"Results 3.2 and Table 1: share reaching a BMI below 27 kg/m2 at week 68 was 41.0% (592/1,444) with the combination, 24.5% (54/220) with semaglutide alone, 13.5% (30/223) with cagrilintide alone and 6.0% (27/451) with placebo."},{"label":"ClinicalTrials.gov NCT05567796 (REDEFINE 1)","url":"https://clinicaltrials.gov/study/NCT05567796","kind":"Registry record","population":"Adults with overweight or obesity","design":"Registered phase 3 randomized trial","locator":"Arms and interventions: four arms (CagriSema, cagrilintide, semaglutide, placebo). Results: none posted on the registry on 2026-11-14."},{"label":"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity in Japan and Taiwan (REDEFINE 5; Lancet Diabetes Endocrinol, 2026; PMID 42009015; DOI 10.1016/s2213-8587(25)00402-4)","url":"https://pubmed.ncbi.nlm.nih.gov/42009015/","kind":"Peer-reviewed paper","population":"331 adults in Japan and Taiwan, with or without type 2 diabetes","design":"Phase 3a randomized, double-blind, active-controlled, 68 weeks, trial-product estimand (a different estimand from REDEFINE 1's primary); funded by Novo Nordisk; registered as NCT05813925","locator":"Abstract: week-68 mean change -18.4% with the combination and -11.9% with semaglutide alone (estimated difference -6.5 percentage points; 95% CI -8.4 to -4.6); adverse events 87% and 84%, gastrointestinal 53% and 51%."},{"label":"FDA alert on compounded injectable semaglutide (content current as of 07/26/2024)","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded","kind":"Regulatory document","population":"Compounded semaglutide products that include added ingredients","design":"FDA alert","locator":"Footnote 1: \"The safety and effectiveness of combining semaglutide with other ingredients has not been established.\" This concerns added ingredients in compounded products, not the CagriSema trials."}],"uncertain":["The component-arm figures come from a secondary post hoc analysis of observed on-treatment data for a different outcome (a BMI target), not from the trial's primary analysis. Body-weight change for the component-alone arms was not retrieved: the paper is behind a subscription and the registry posts no results.","Both trials were funded by the sponsor of both medicines, and the post hoc analysis includes sponsor employees as authors.","A positive result for one combination in one population does not transfer to other combinations, populations or settings, and a combination can add side effects. Combination-versus-component adverse-event comparisons from REDEFINE 1 were not retrieved.","REDEFINE 1 and REDEFINE 5 used different estimands, so their weight-change figures are not directly comparable.","Regulatory status as of 2026-11-14 (United States): FDA's Novel Drug Approvals pages for 2025 (content current 07/08/2026) and 2026 (content current 11/09/2026) list no cagrilintide or CagriSema product, and an openFDA Drugs@FDA search for cagrilintide returned no match. A company announcement dated 2025-12-18 says an FDA application was filed. FDA does not publish pending applications, so review status cannot be confirmed from an official record. Status in the EU, the UK and elsewhere was not determined from official records."],"wouldChange":["Registry results or the full REDEFINE 1 paper reporting outcomes and adverse events for each arm, which would let a reader see what the combination added to each component.","A randomized trial of any other combination of interest, with component-alone arms and safety reporting, which would support a statement limited to that trial's combination and population."],"gaps":["Body-weight change and adverse events for the semaglutide-alone and cagrilintide-alone arms of REDEFINE 1 were not retrieved.","The full texts of REDEFINE 1 and REDEFINE 5 were not read.","No regulator outside the United States was checked."],"searchScope":null,"regulatory":null,"checkedOn":"2026-11-14","links":{"profiles":["/directory/semaglutide"],"films":[],"flagship":["https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management"],"journeys":["/research/journey/semaglutide"],"teaching":[],"changes":[]},"extends1_0_0":false},"sha256":"8b2368d2b6976b22c4f0bbbc6461f5fbf629e8ff4634f7edf56dbe76e29d7268"}